By the PharmaTradz BD Team. Published November 2026.
In short: US tariffs of up to 100% on patented medicines and their APIs, with lower rates for companies that build US plants, are driving a wave of big-pharma manufacturing investment in the United States. Most of those plants will not produce until 2029 to 2031. Generics and biosimilars are not tariffed for now, so global generic supply chains are largely unaffected, but contract manufacturers and API suppliers serving branded products need to plan for shifting volumes.
On 13 November 2026, one of the world's largest obesity-drug makers broke ground on a US$3.5 billion plant in Pennsylvania to make next-generation obesity medicines, with operations expected by 2031 (BioProcess International). It is one of many such announcements this year. Behind them is a single policy: Section 232 pharmaceutical tariffs.
How the tariffs work
- The base rate. A proclamation of 2 April 2026 set a tariff of up to 100% on patented medicines and on listed APIs and key starting materials. It took effect on 29 September 2026 for most companies (Federal Register).
- Lower rates for investment. Companies with Commerce-approved US manufacturing plans pay 20%, rising to 100% four years after the proclamation. Companies that combine US manufacturing commitments with most-favoured-nation pricing deals pay 0% until 20 January 2029 (EY).
- Lower rates for trade partners. Products from the EU, Japan, South Korea, Switzerland and Liechtenstein face 15%, and the UK 10%.
- Generics and biosimilars are excluded for now. The Commerce Department must report within a year on whether generics need action.
- Specialty products at 0%. From 29 September, categories such as orphan-only drugs, plasma-derived therapies, cell and gene therapies, antibody-drug conjugates and fertility medicines can enter at 0% from 19 listed jurisdictions, including the EU, UK, Japan, India, Korea and several Southeast Asian and Latin American countries (Lighthill).
The US Commerce Department estimates that about 53% of patented drugs sold in the US are made abroad, and only about 15% of patented API volume is made domestically. That gap is what the tariffs are designed to close.
Why onshoring is slower than the headlines
A new sterile or API plant typically takes four to six years from groundbreaking to approved commercial supply: construction, equipment qualification, process validation, regulatory inspection and product transfer. The Pennsylvania plant above is expected to operate by 2031. Meanwhile the 0% rate for companies with pricing deals runs to January 2029. For the next few years, most branded products sold in the US will still be made where they are made today, with tariffs avoided through deals, trade-partner rates or exemptions.
What it means for global CDMOs and API makers
- Branded volumes will gradually shift. Contract manufacturers making patented products for the US market should expect some customers to move production to US sites from 2028 onwards. Contracts with renewal dates after that deserve attention now.
- US capacity needs partners. New US plants need APIs, intermediates, excipients, components and technical staff. Suppliers to those plants, wherever they are based, gain business even as finished production moves.
- Tariff-advantaged locations gain. Sites in the EU, Japan, Korea and Switzerland have a 15% rate rather than 100%, which strengthens their position for patented products versus sites in countries without an agreement.
- Generic supply chains stay global for now. With generics excluded, the main question is what Commerce recommends on generics; we covered that risk in our analysis of possible tariffs from 2028.
What it means for buyers outside the US
Capacity spent on US onshoring is capacity not spent elsewhere. As originators redirect capital and technical talent to US projects, some will consolidate older sites that serve other markets. Buyers in Europe, the Middle East and Asia should watch for site transfers and discontinuations of older brands, which often trigger shortages and opportunities for generic alternatives.
Our view
We think US onshoring is real, but it will reshape where new branded medicines are made, not where most of the world's medicines come from. Generics, which make up the large majority of prescriptions globally, remain a global business built on cost and scale, and tariffs on them would raise US costs sharply, which is why they were left out. The bigger near-term effect is indirect: capital, people and attention flowing into US projects while older global sites are rationalised.
For manufacturers outside the US, the smart move is to become indispensable to the new US plants as suppliers of APIs, intermediates and specialised services, and to strengthen positions in markets the onshoring wave will not touch. For buyers, it is to qualify alternative sources early for older products whose production may move or stop.
Related reading on PharmaTradz
- US pharma tariffs: what API and finished-dose buyers need to know
- US tariffs on generic medicines from 2028
- API price trends 2026
- Check discontinuations and shortages: drug shortage radar
- Need an alternative source? Send your requirement
The bottom line
Tariffs are pulling branded manufacturing into the US, but the new plants arrive at the end of the decade. Until then, the opportunity for global suppliers is to feed the build-out and to fill the gaps it leaves elsewhere.
This article is general business information, not legal, tax or trade advice. Tariff rates and exemptions change by notice; check the current position with the relevant authority or a qualified adviser.
Frequently Asked Questions(FAQs)
What are the US Section 232 pharmaceutical tariffs?
Tariffs of up to 100% on patented medicines and listed APIs and key starting materials, in force for most companies from 29 September 2026, with lower rates for US investment, pricing deals and trade partners.
Are generic medicines subject to the tariffs?
Not at present. Generics and biosimilars are excluded, and the US Commerce Department is due to report within a year on whether they need action.
Which countries get lower tariff rates?
The EU, Japan, South Korea, Switzerland and Liechtenstein face 15%, and the UK 10%. Some specialty products enter at 0% from 19 listed jurisdictions.
When will new US pharma plants start producing?
Mostly from 2029 to 2031. A sterile or API plant typically takes four to six years from groundbreaking to approved commercial supply.
How should contract manufacturers outside the US respond?
Review branded contracts that renew after 2028, offer APIs and services to the new US plants, and strengthen positions in generics and in markets outside the US.